Mr. Doug Drysdale reports

CYBIN PARTNERS WITH WORLDWIDE CLINICAL TRIALS TO SUPPORT FUTURE CLINICAL DEVELOPMENT OF CYB003 IN MAJOR DEPRESSIVE DISORDER

Cybin Inc. has partnered with Worldwide Clinical Trials, a global, full-service contract research organization (CRO) with deep expertise managing clinical trials for mental health conditions, including major depressive disorder. To date, the partnership with Worldwide has been pivotal in the development of study designs, defining global regulatory strategy and navigation of regulatory pathways, and pharmacovigilance.

Worldwide has a record of successful patient recruitment for psychedelic trials and global relationships with best-in-class investigative sites. Worldwide has recent experience managing 11 psychedelic studies in psychiatric populations, including phase I and phase II clinical trials conducted in the United States, Canada, the United Kingdom and other European countries, across a range of psychedelic compounds and treatment models.

"We are proud to align with Worldwide, a distinguished CRO with a proven track record of supporting industry-sponsored psychedelic clinical trials," said Doug Drysdale, chief executive officer of Cybin. "Worldwide brings significant regulatory, logistical and operational expertise as a leader in psychedelic clinical research, making Worldwide the ideal partner for navigating the regulatory landscape surrounding the development of psychedelic-based therapeutics."

"At Worldwide, we share a passion for Cybin's mission to revolutionize mental health care," said Dr. Michael Murphy, chief medical and scientific officer of Worldwide Clinical Trials. "We are proud to partner with such a diverse and extraordinary group of experts to help create safe and effective psychedelic-based therapies to transform potential treatment options for patients who live with mental health disorders."

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT (dimethyltryptamine) molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

We seek Safe Harbor.